Description: ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
Home Page: www.immupharma.co.uk
IMM Technical Analysis
1 Bartholomew Close
London,
EC1A 7BL
United Kingdom
Phone:
44 20 7206 2650
Officers
| Name | Title |
|---|---|
| Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA | Chairman & CEO |
| Dr. Timothy Gary Franklin M.B.A., Ph.D. | COO & Director |
| Ms. Lisa Baderoon | Head of Investor Relations & Non Exec. Director |
| Dr. Jean-Marie Geiger PharmD, MD | Head of Clinical Devel. |
| Dr. Laura Mauran-Ambrosino | Chief Scientific Officer of ImmuPharma Biotech |
| Dr. Sébastien R. Goudreau Ph.D. | Chief Exec. Officer of ImmuPharma Biotec |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4968 |
| Price-to-Sales TTM: | 81.0485 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |